论文部分内容阅读
通过对４７例大肠良性疾病及５２例大肠恶性肿瘤分别进行大肠粘液双糖残基β－Ｄ－Ｇａｌ（１→３）－Ｄ－ＧａｌＮＡＣ的检测及粪便ＣＥＡ测定，前者阳性率为８２．７％、假阴性率为１７．３％，后者阳性率为７６．９％。假阴性率为２３．１％。两者ＣＥＡ水平：良性疾病组１．７０±０．１５μｇ／ｇ，恶性肿瘤组５．１０±０．２６μｇ／ｇ，两组比较Ｐ＜０．０１。两种检测综合阳性率８８．６％，假阴性率１１．４％。作者认为这两种检测有较高的阳性率及较低的阴性率，适合于对高危人群进行大肠癌普查。
The detection of β-D-Gal(1→3)-D-GalNAC in the large intestine mucous and the stool CEA were performed in 47 cases of benign colorectal disease and 52 cases of large intestine malignant tumor. The positive rate of the former was 82.7%. The false negative rate was 17.3%, and the latter positive rate was 76.9%. The false negative rate was 23.1%. Both CEA levels were 1.70±0.15 μg/g in the benign disease group and 5.10±0.26 μg/g in the malignant tumor group. The difference between the two groups was P<0.01. The combined positive rate of the two tests was 88.6%, and the false negative rate was 11.4%. The authors believe that these two tests have a higher positive rate and a lower negative rate, and are suitable for the screening of high-risk groups for colorectal cancer.